MoneyWorks4Me

Dr. Reddy’s Laboratories informs about press release

27 Feb 2023 Evaluate

Dr. Reddy’s Laboratories has informed that it enclosed a Press Release on ‘Dr. Reddy's Laboratories announces agreement to acquire Mayne Pharma’s U.S. generic prescription product portfolio’.

The above information is a part of company’s filings submitted to BSE.


Dr. Reddys Labs. Share Price

1180.50 -11.50 (-0.96%)
18-Aug-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1876.40
Dr. Reddys Labs. 1180.50
Cipla 1431.85
Lupin 2225.00
Zydus Lifesciences 1117.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: